. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: Cancer Discov. 2019 May 20;9(8):1064–1079. doi: 10.1158/2159-8290.CD-19-0182

Table 1B.

Detection of FGFR2 mutations in ctDNA and tumor biopsies

Patient ID	FGFR2 Fusion	Post-Progression BGJ398/Debio1347, Prior to TAS-120		Post-Progression TAS-120
Patient ID	FGFR2 Fusion	cfDNA	Tumor Biopsy	cfDNA	Tumor Biopsy
1	FGFR2-SORBS1	K660M, K715R	None Detected	V565F^&	V565F^&&
2	FGFR2-ZMYM4	V565F, K660M, E566A, N550H, N550K	V565F^&&, K660M^&&	V565F, K660M, E566A, N550H, N550K, V563L	V563L
3	FGFR2-INA	H683L^&, L618V^&	Biopsy #1: H683L Biopsy #2: N550H, N550T, M538I	V565L, E566A, N550H, L618V, N550T^&, M538I^&	No Biopsy Obtained
4	FGFR2-NRAP	None Detected	No Biopsy Obtained	N550K	N550K

All mutations were detected on CLIA-certified assays as a routine part of clinical care except those designated with an ^&(detected on ddPCR only) or ^&&(detected on WES only).